MA42527A - Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation - Google Patents

Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Info

Publication number
MA42527A
MA42527A MA042527A MA42527A MA42527A MA 42527 A MA42527 A MA 42527A MA 042527 A MA042527 A MA 042527A MA 42527 A MA42527 A MA 42527A MA 42527 A MA42527 A MA 42527A
Authority
MA
Morocco
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
MA042527A
Other languages
English (en)
Inventor
Konrad Feichtinger
Juerg Lehmann
Albert S Ren
Graeme Semple
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA42527A publication Critical patent/MA42527A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA042527A 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation MA42527A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
MA42527A true MA42527A (fr) 2021-04-07

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042527A MA42527A (fr) 2015-07-31 2016-07-28 Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Country Status (14)

Country Link
US (4) US10272094B2 (fr)
EP (1) EP3328835B1 (fr)
JP (1) JP6789578B2 (fr)
KR (1) KR20180031035A (fr)
CN (1) CN108137508B (fr)
AU (1) AU2016302755B2 (fr)
BR (1) BR112018001707A2 (fr)
CA (1) CA3002525A1 (fr)
EA (1) EA039412B1 (fr)
HK (1) HK1255850A1 (fr)
IL (1) IL257107B (fr)
MA (1) MA42527A (fr)
MX (1) MX2018001380A (fr)
WO (1) WO2017023679A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42527A (fr) * 2015-07-31 2021-04-07 Arena Pharm Inc Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3733204A4 (fr) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
EP3955936A1 (fr) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Traitement de la dépression et de divers autres troubles au moyen de psilocybine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018005A1 (fr) 1991-04-16 1992-10-29 National Institutes Of Health Procede de traitement de la trichotillomanie et de l'onychophagie
WO2003086303A2 (fr) 2002-04-12 2003-10-23 The University Of Chicago Agonistes de recepteur active frx (farnesoid x receptor)
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
CN101792417A (zh) * 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
EP2824106B1 (fr) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Composé tricyclique
MA42527A (fr) 2015-07-31 2021-04-07 Arena Pharm Inc Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation

Also Published As

Publication number Publication date
US10624900B2 (en) 2020-04-21
US20200383993A1 (en) 2020-12-10
CN108137508B (zh) 2021-08-27
EP3328835A1 (fr) 2018-06-06
IL257107A (en) 2018-03-29
NZ739883A (en) 2021-03-26
EA039412B1 (ru) 2022-01-25
HK1255850A1 (zh) 2019-08-30
BR112018001707A2 (pt) 2018-09-18
KR20180031035A (ko) 2018-03-27
AU2016302755B2 (en) 2020-09-10
WO2017023679A1 (fr) 2017-02-09
US10272094B2 (en) 2019-04-30
US20200078368A1 (en) 2020-03-12
IL257107B (en) 2021-03-25
AU2016302755A1 (en) 2018-03-15
EA201890402A1 (ru) 2018-09-28
JP6789578B2 (ja) 2020-11-25
US20180214455A1 (en) 2018-08-02
EP3328835B1 (fr) 2022-10-12
US11395824B2 (en) 2022-07-26
MX2018001380A (es) 2018-06-15
CN108137508A (zh) 2018-06-08
JP2018522025A (ja) 2018-08-09
CA3002525A1 (fr) 2017-02-09
US20230055376A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
HK1257751A1 (zh) 類法尼醇x受體激動劑及其用途
MA41613A (fr) Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
MA53246A (fr) Composés et procédés pour favoriser la myélinisation
HK1244005B (zh) 5-ht2c受體激動劑和組合物和使用方法
IL248347A0 (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311A0 (en) Compounds and preparations as agonists of toll-like receptor 7
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA42527A (fr) Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
DK3368060T3 (da) Glugacon-receptor-agonister
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
MA44392A (fr) Procédés d'utilisation d'activateurs de la pyruvate kinase
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
IL264682B (en) 5-HT2C receptor agonists and preparations and methods of use
MA39915A (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA45573A (fr) Anticorps anti-cd154 et procédés d'utilisation correspondant
MA45047A (fr) Procédés d'utilisation d'inhibiteurs de fasn
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
MA52920A (fr) Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f
FR3045851B1 (fr) Dispositif de maintien et de liberation d'appendices